Skip to main
TNDM
TNDM logo

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 16 analyst ratings
Hold
Strong Buy 6%
Buy 25%
Hold 69%
Sell 0%
Strong Sell 0%

Bulls say

Tandem Diabetes Care has successfully positioned itself in the insulin pump market since its 2012 entry, with its product lineup now including the advanced t:slim X2 and the recently launched Mobi pump, indicating ongoing innovation and product development. Approximately 75% of the company’s revenue comes from the United States, where its durable insulin pumps and disposable infusion sets account for a significant portion of total sales, reflecting a strong customer base and recurring revenue model. Despite facing increased competition and a need to retain customers, the firm maintains its revenue estimates, showcasing confidence in sustained growth potential amid market dynamics.

Bears say

Tandem Diabetes Care has consistently reported significant operating losses since its inception, raising concerns about its ability to achieve sustained profitability in the future. Furthermore, uncertainty in global economic and political conditions introduces additional risks that could hinder the company's ability to predict product demand, thereby negatively impacting financial results. Although there are expectations of achieving positive adjusted EBITDA by Q3 2025, the projected slower ramp in profitability due to increased investments in commercial infrastructure presents further challenges for the company's financial outlook.

TNDM has been analyzed by 16 analysts, with a consensus rating of Hold. 6% of analysts recommend a Strong Buy, 25% recommend Buy, 69% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Hold based on their latest research and market trends.

According to 16 analysts, TNDM has a Hold consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.